全文获取类型
收费全文 | 121155篇 |
免费 | 9442篇 |
国内免费 | 3589篇 |
专业分类
耳鼻咽喉 | 1528篇 |
儿科学 | 2954篇 |
妇产科学 | 1536篇 |
基础医学 | 21646篇 |
口腔科学 | 2123篇 |
临床医学 | 8765篇 |
内科学 | 21336篇 |
皮肤病学 | 3289篇 |
神经病学 | 7422篇 |
特种医学 | 3263篇 |
外国民族医学 | 29篇 |
外科学 | 11545篇 |
综合类 | 13294篇 |
现状与发展 | 15篇 |
预防医学 | 5506篇 |
眼科学 | 1981篇 |
药学 | 14375篇 |
6篇 | |
中国医学 | 3738篇 |
肿瘤学 | 9835篇 |
出版年
2024年 | 170篇 |
2023年 | 2171篇 |
2022年 | 3093篇 |
2021年 | 5474篇 |
2020年 | 4117篇 |
2019年 | 5144篇 |
2018年 | 5164篇 |
2017年 | 4372篇 |
2016年 | 3525篇 |
2015年 | 4216篇 |
2014年 | 6458篇 |
2013年 | 7271篇 |
2012年 | 5989篇 |
2011年 | 7293篇 |
2010年 | 5870篇 |
2009年 | 6125篇 |
2008年 | 5799篇 |
2007年 | 5460篇 |
2006年 | 4790篇 |
2005年 | 4208篇 |
2004年 | 3862篇 |
2003年 | 3464篇 |
2002年 | 3650篇 |
2001年 | 3454篇 |
2000年 | 3608篇 |
1999年 | 2585篇 |
1998年 | 2481篇 |
1997年 | 2232篇 |
1996年 | 1631篇 |
1995年 | 1345篇 |
1994年 | 1008篇 |
1993年 | 822篇 |
1992年 | 657篇 |
1991年 | 616篇 |
1990年 | 496篇 |
1989年 | 426篇 |
1988年 | 339篇 |
1987年 | 292篇 |
1986年 | 298篇 |
1985年 | 591篇 |
1984年 | 665篇 |
1983年 | 418篇 |
1982年 | 483篇 |
1981年 | 405篇 |
1980年 | 357篇 |
1979年 | 300篇 |
1978年 | 231篇 |
1977年 | 203篇 |
1976年 | 196篇 |
1975年 | 132篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
101.
目的:研究D-二聚体(D-dimer,D-D)和中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)与卵巢癌临床病理特征及预后的关系。方法:回顾性分析2012年1月至2015年12月于我院妇科行手术治疗的卵巢恶性肿瘤患者387例和卵巢良性肿瘤患者250例临床资料。比较血清D-D和外周血NLR在卵巢良、恶性肿瘤中的表达水平;确定D-D和NLR临界值,D-D+NLR=0(D-D≤0.555 mg/L和NLR≤2.792),D-D+NLR=1(D-D>0.555 mg/L或NLR>2.792),D-D+NLR=2(D-D>0.555 mg/L和NLR>2.792),分析两者联合的评分系统与卵巢癌临床病理特征和预后的关系。结果:血清D-D和外周血NLR在卵巢良、恶性肿瘤患者中的表达水平有统计学差异(P<0.001)。D-D高水平组与低水平组相比,患者的分期、分级、淋巴结转移、腹水、CA125水平、残余瘤大小有统计学差异(P<0.05)。NLR高水平组与低水平组相比,患者的年龄、分期、淋巴结转移、腹水、CA125水平、残余瘤大小有统计学差异(P<0.05)。D-D+NLR为0、1、2分的平均总生存期(OS)分别为70个月、58个月、40个月。D-D+NLR评分是影响OS的独立预后因素。结论:术前血清D-D和外周血NLR与卵巢癌临床病理特征和OS相关,D-D+NLR评分可以作为评估卵巢癌预后的指标。 相似文献
103.
104.
105.
白细胞介素4(IL-4)是T辅助2(Th2)介导的免疫反应的基本免疫调节细胞因子,IL-4具有复杂的信号系统和多效的功能,但在脑组织中,诸多研究发现IL-4可在炎症中保护认知功能。该文总结了关于IL-4保护认知功能的证据及机制,以及在阿尔茨海默病、缺血性脑血管病以及手术后认知功能障碍中IL-4保护认知功能的途径及证据。 相似文献
106.
Phonphimon Wongthida Matthew R Schuelke Christopher B Driscoll Timothy Kottke Jill M Thompson Jason Tonne Cathy Stone Amanda L Huff Cynthia Wetmore James A Davies Alan L Parker Laura Evgin Richard G Vile 《Neuro-oncology》2020,22(12):1757
BackgroundDiffuse midline glioma, formerly DIPG (diffuse intrinsic pontine glioma), is the deadliest pediatric brainstem tumor with median survival of less than one year. Here, we investigated (i) whether direct delivery of adenovirus-expressing cluster of differentiation (CD)40 ligand (Ad-CD40L) to brainstem tumors would induce immune-mediated tumor clearance and (ii) if so, whether therapy would be associated with a manageable toxicity due to immune-mediated inflammation in the brainstem.MethodsSyngeneic gliomas in the brainstems of immunocompetent mice were treated with Ad-CD40L and survival, toxicity, and immune profiles determined. A clinically translatable vector, whose replication would be tightly restricted to tumor cells, rAd-Δ24-CD40L, was tested in human patient–derived diffuse midline gliomas and immunocompetent models.ResultsExpression of Ad-CD40L restricted to brainstem gliomas by pre-infection induced complete rejection, associated with immune cell infiltration, of which CD4+ T cells were critical for therapy. Direct intratumoral injection of Ad-CD40L into established brainstem tumors improved survival and induced some complete cures but with some acute toxicity. RNA-sequencing analysis showed that Ad-CD40L therapy induced neuroinflammatory immune responses associated with interleukin (IL)-6, IL-1β, and tumor necrosis factor α. Therefore, to generate a vector whose replication, and transgene expression, would be tightly restricted to tumor cells, we constructed rAd-Δ24-CD40L, the backbone of which has already entered clinical trials for diffuse midline gliomas. Direct intratumoral injection of rAd-Δ24-CD40L, with systemic blockade of IL-6 and IL-1β, generated significant numbers of cures with readily manageable toxicity.ConclusionsVirus-mediated delivery of CD40L has the potential to be effective in treating diffuse midline gliomas without obligatory neuroinflammation-associated toxicity. 相似文献
107.
《Clinical therapeutics》2019,41(5):836-847
PurposeA role for the immune system in causing myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) is long suspected, but few studies have looked for specific autoantibodies that might contribute to the symptoms. Our aim was to look for evidence of antibodies to neuronal proteins in patients with ME/CSF.MethodsSera samples from 50 patients and 50 healthy individuals were sent coded to the Neuroimmunology Laboratory in Oxford. Screening for antibody binding to neuronal tissue was performed on brain tissue and neuronal cultures. Specific serum antibodies were assessed by antigen-specific cell-based assays and radioimmunoassays. After antibody testing, the associations between seropositive status and clinical data were investigated.FindingsOverall, 8 patients and 11 participants were found to have some serum immunoreactivity toward neuronal or neuromuscular junction proteins, but only 1 patient and 2 participants had specific serum antibodies. Nevertheless, seropositive status in patients with ME was associated with shorter duration since onset and a more severe disease.ImplicationsThe results indicate no overall increased frequency of antibodies to neuronal proteins in ME/CSF and no evidence of a specific antibody that might be causative or contribute to clinical features in patients. However, the association of seropositive status with shorter duration of disease and more severe symptoms suggests a possible role of antibodies at onset in some patients and should be the focus of future studies. 相似文献
108.
109.
《药学学报(英文版)》2020,10(7):1294-1308
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds with therapeutic advantages over single target inhibitors and drug combinations. Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent in vitro and in vivo antitumor potency. Particularly, compound 30a was orally active and possessed excellent in vivo antitumor activity in the HCT116 xenograft model (TGI = 75.2%, 150 mg/kg, p.o.) without significant toxicity, which was more potent than HDAC inhibitor vorinostat, TOP inhibitor evodiamine and their combination. Taken together, this study highlights the therapeutic advantages of evodiamine-based HDAC1/TOP2 dual inhibitors and provides valuable leads for the development of novel multi-targeting antitumor agents. 相似文献
110.